Cara A. Rabik

2.3k total citations · 1 hit paper
14 papers, 1.6k citations indexed

About

Cara A. Rabik is a scholar working on Molecular Biology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Cara A. Rabik has authored 14 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Cara A. Rabik's work include Acute Lymphoblastic Leukemia research (4 papers), Metal complexes synthesis and properties (3 papers) and Acute Myeloid Leukemia Research (2 papers). Cara A. Rabik is often cited by papers focused on Acute Lymphoblastic Leukemia research (4 papers), Metal complexes synthesis and properties (3 papers) and Acute Myeloid Leukemia Research (2 papers). Cara A. Rabik collaborates with scholars based in United States, Netherlands and Denmark. Cara A. Rabik's co-authors include M. Eileen Dolan, M. Eileen Dolan, Kristen Kasza, Melissa L. Fishel, Edward B. Maryon, J. T. Shafer, Merrill J. Egorin, Mark R. Kelley, Julianne L. Holleran and Teri E. Klein and has published in prestigious journals such as Blood, Clinical Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Cara A. Rabik

12 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular mechanisms of resistance and toxicity associated with platinating agents

2006 1.3k citations Cara A. Rabik, M. Eileen Dolan Cancer Treatment Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cara A. Rabik United States	8	740	738	291	205	193	14	1.6k
Sara M. Schmitt United States	14	834 1.1×	1.0k 1.4×	451 1.5×	168 0.8×	117 0.6×	20	1.9k
Nicole A. Seebacher Australia	18	676 0.9×	690 0.9×	187 0.6×	196 1.0×	125 0.6×	24	1.4k
Ganna V. Kalayda Germany	18	1.0k 1.4×	630 0.9×	545 1.9×	151 0.7×	130 0.7×	38	1.7k
Maria Kartalou United States	9	658 0.9×	1.0k 1.4×	232 0.8×	241 1.2×	217 1.1×	9	1.5k
Michael Frezza United States	14	1.0k 1.4×	847 1.1×	640 2.2×	119 0.6×	106 0.5×	15	1.9k
Ding‐Wu Shen United States	18	999 1.4×	1.1k 1.6×	313 1.1×	287 1.4×	182 0.9×	24	2.1k
Youzhi Li China	13	490 0.7×	695 0.9×	252 0.9×	152 0.7×	154 0.8×	41	1.7k
Dimitrios T. Trafalis Greece	20	792 1.1×	957 1.3×	300 1.0×	303 1.5×	115 0.6×	113	2.2k
Gabriella Pezzoni Italy	24	885 1.2×	913 1.2×	539 1.9×	100 0.5×	133 0.7×	45	1.9k
Nives Carenini Italy	27	934 1.3×	1.4k 1.9×	452 1.6×	199 1.0×	149 0.8×	62	2.1k

Countries citing papers authored by Cara A. Rabik

Since Specialization

Citations

This map shows the geographic impact of Cara A. Rabik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cara A. Rabik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cara A. Rabik more than expected).

Fields of papers citing papers by Cara A. Rabik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cara A. Rabik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cara A. Rabik. The network helps show where Cara A. Rabik may publish in the future.

Co-authorship network of co-authors of Cara A. Rabik

This figure shows the co-authorship network connecting the top 25 collaborators of Cara A. Rabik. A scholar is included among the top collaborators of Cara A. Rabik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cara A. Rabik. Cara A. Rabik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Pui, CH, et al.. (2026). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. Clinical Pharmacology & Therapeutics. 119(4). 916–927.

Rabik, Cara A., Shu Wang, Donna Przepiorka, et al.. (2025). FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy. Clinical Cancer Research. 31(20). 4230–4238.

Cheng, Connie, et al.. (2024). Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature. Pediatric Hematology and Oncology. 41(7). 519–529. 2 indexed citations

Rabik, Cara A., et al.. (2021). Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients. Expert Opinion on Investigational Drugs. 30(6). 611–620. 4 indexed citations

Zwaan, C. Michel, et al.. (2019). A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 3937–3937. 1 indexed citations

Annesley, Colleen, Cara A. Rabik, Amy S. Duffield, et al.. (2018). Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget. 9(82). 35313–35326. 7 indexed citations

Rabik, Cara A., et al.. (2017). Treatment of an acquired Factor XIII inhibitor in an adolescent with systemic lupus erythematosus and renal failure. Transfusion. 57(9). 2159–2163. 3 indexed citations

Marsh, Sharon, Howard L. McLeod, M. Eileen Dolan, et al.. (2009). Platinum pathway. Pharmacogenetics and Genomics. 19(7). 563–564. 37 indexed citations

Rabik, Cara A., Melissa L. Fishel, Julianne L. Holleran, et al.. (2008). Enhancement of Cisplatin [cis-Diammine Dichloroplatinum (II)] Cytotoxicity by O6-Benzylguanine Involves Endoplasmic Reticulum Stress. Journal of Pharmacology and Experimental Therapeutics. 327(2). 442–452. 33 indexed citations

10.

Rabik, Cara A., et al.. (2008). Role of copper transporters in resistance to platinating agents. Cancer Chemotherapy and Pharmacology. 64(1). 133–142. 36 indexed citations

11.

Rabik, Cara A. & M. Eileen Dolan. (2006). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treatment Reviews. 33(1). 9–23. 1321 indexed citations breakdown →

12.

Kathju, Sandeep, Latha Satish, Cara A. Rabik, et al.. (2006). Identification of differentially expressed genes in scarless wound healing utilizing polymerase chain reaction‐ suppression subtractive hybridization. Wound Repair and Regeneration. 14(4). 413–420. 22 indexed citations

13.

Rabik, Cara A., et al.. (2006). Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treatment Reviews. 32(4). 261–276. 75 indexed citations

14.

Fishel, Melissa L., Cara A. Rabik, Wasim K. Bleibel, et al.. (2005). Role of GADD34 in modulation of cisplatin cytotoxicity. Biochemical Pharmacology. 71(3). 239–247. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact